Trial Profile
Neuro-cognitive impairment and associated symptoms in HIV-positive patients who switch from efavirenz-based cART to Emtricitabine/rilpivirine/tenofovir-disoproxil-fumarate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2017
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 02 Jan 2017 New trial record